AVIDITY BIOSCIENCES INC (RNA) Stock Price, Quote, News and Overview
NASDAQ:RNA - Nasdaq - US05370A1088 - Common Stock - Currency: USD
RNA Quote, Performance and Key Statistics
29.45
+0.93 (+3.26%)
The current stock price of RNA is 29.45 USD. In the past month the price decreased by -11.56%. In the past year, price increased by 20.89%.
RNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About RNA
Company Profile
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 391 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Company Info
AVIDITY BIOSCIENCES INC
10578 Science Center Drive, Suite 125
San Diego CALIFORNIA 92037 US
CEO: Sarah Boyce
Employees: 391
Company Website: https://www.aviditybiosciences.com/
Investor Relations: https://aviditybiosciences.investorroom.com/
Phone: 18584017900
AVIDITY BIOSCIENCES INC / RNA FAQ
What is the stock price of AVIDITY BIOSCIENCES INC today?
The current stock price of RNA is 29.45 USD. The price increased by 3.26% in the last trading session.
What is the ticker symbol for AVIDITY BIOSCIENCES INC stock?
The exchange symbol of AVIDITY BIOSCIENCES INC is RNA and it is listed on the Nasdaq exchange.
On which exchange is RNA stock listed?
RNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVIDITY BIOSCIENCES INC stock?
17 analysts have analysed RNA and the average price target is 68.18 USD. This implies a price increase of 131.52% is expected in the next year compared to the current price of 29.45. Check the AVIDITY BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVIDITY BIOSCIENCES INC worth?
AVIDITY BIOSCIENCES INC (RNA) has a market capitalization of 3.54B USD. This makes RNA a Mid Cap stock.
How many employees does AVIDITY BIOSCIENCES INC have?
AVIDITY BIOSCIENCES INC (RNA) currently has 391 employees.
What are the support and resistance levels for AVIDITY BIOSCIENCES INC (RNA) stock?
AVIDITY BIOSCIENCES INC (RNA) has a support level at 25.76 and a resistance level at 29.7. Check the full technical report for a detailed analysis of RNA support and resistance levels.
Is AVIDITY BIOSCIENCES INC (RNA) expected to grow?
The Revenue of AVIDITY BIOSCIENCES INC (RNA) is expected to decline by -26.63% in the next year. Check the estimates tab for more information on the RNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVIDITY BIOSCIENCES INC (RNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RNA, evaluating the profitability, health, valuation and growth aspects
- AVIDITY BIOSCIENCES INC (RNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVIDITY BIOSCIENCES INC (RNA) Sales and EPS estimates to see what analysts future expectations are.
- AVIDITY BIOSCIENCES INC (RNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVIDITY BIOSCIENCES INC (RNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVIDITY BIOSCIENCES INC (RNA) Stock Chart to make your own analysis
- AVIDITY BIOSCIENCES INC (RNA) Latest news and press-releases to stay up to date.
Does AVIDITY BIOSCIENCES INC (RNA) stock pay dividends?
RNA does not pay a dividend.
When does AVIDITY BIOSCIENCES INC (RNA) report earnings?
AVIDITY BIOSCIENCES INC (RNA) will report earnings on 2025-05-13, after the market close.
What is the Price/Earnings (PE) ratio of AVIDITY BIOSCIENCES INC (RNA)?
AVIDITY BIOSCIENCES INC (RNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.89).
What is the Short Interest ratio of AVIDITY BIOSCIENCES INC (RNA) stock?
The outstanding short interest for AVIDITY BIOSCIENCES INC (RNA) is 15.04% of its float. Check the ownership tab for more information on the RNA short interest.
RNA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RNA. When comparing the yearly performance of all stocks, RNA is one of the better performing stocks in the market, outperforming 87.1% of all stocks.
RNA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RNA. RNA has a great financial health rating, but its profitability evaluates not so good.
RNA Financial Highlights
Over the last trailing twelve months RNA reported a non-GAAP Earnings per Share(EPS) of -2.89. The EPS increased by 0.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.61% | ||
| ROE | -22.62% | ||
| Debt/Equity | 0 |
RNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to RNA. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -36.18% and a revenue growth -26.63% for RNA